Video

MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.

Related Videos
Dr. Richard “Rick" Winneker
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with brown hair.
Related Content
Illustration of blood cells.
March 16th 2025

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

Spencer Feldman
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Illustration of red blood cells.
January 20th 2025

Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis

Alex Biese
Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.